Vildagliptin

Human medicines European public assessment report (EPAR): Icandra (previously Vildagliptin / metformin hydrochloride Novartis), vildagliptin,metformin, Date of authorisation: 30/11/2008, Revision: 26, Status: Authorised

Retrieved on: 
Monday, January 8, 2024
Patient, Liver, Medical Subject Headings, Diarrhea, Marketing, INN, Woman, Allergy, ATC, Absorption, Hormone, Pain, International, Diet, Pancreas, Insulin, Disease, Diabetes, Metformin, Blood, Nausea, Somatic symptom disorder, Language, DPP-4, Type, Glucose, European Medicines Agency, Type 2 diabetes, Food, Kidney, Metabolic acidosis, Tablet, Select, Alcoholism, Anatomy, Vildagliptin, IIA, Exercise, Vomiting, Medical device

Human medicines European public assessment report (EPAR): Icandra (previously Vildagliptin / metformin hydrochloride Novartis), vildagliptin,metformin, Date of authorisation: 30/11/2008, Revision: 26, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Icandra (previously Vildagliptin / metformin hydrochloride Novartis), vildagliptin,metformin, Date of authorisation: 30/11/2008, Revision: 26, Status: Authorised

Human medicines European public assessment report (EPAR): Eucreas, vildagliptin,metformin, Date of authorisation: 14/11/2007, Revision: 24, Status: Authorised

Retrieved on: 
Monday, January 8, 2024
Patient, Liver, Medical Subject Headings, Diarrhea, Marketing, INN, Woman, Allergy, ATC, Absorption, Hormone, Pain, International, Diet, Pancreas, Insulin, Disease, Diabetes, Metformin, Blood, Nausea, Somatic symptom disorder, Language, DPP-4, Type, Glucose, European Medicines Agency, Type 2 diabetes, Food, Metabolic acidosis, Kidney, Tablet, Select, Alcoholism, Anatomy, Vildagliptin, IIA, Exercise, Vomiting, Medical device

Human medicines European public assessment report (EPAR): Eucreas, vildagliptin,metformin, Date of authorisation: 14/11/2007, Revision: 24, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Eucreas, vildagliptin,metformin, Date of authorisation: 14/11/2007, Revision: 24, Status: Authorised

Human medicines European public assessment report (EPAR): Zomarist, vildagliptin,metformin, Date of authorisation: 30/11/2008, Revision: 24, Status: Authorised

Retrieved on: 
Monday, January 8, 2024
Patient, Liver, Medical Subject Headings, Diarrhea, Marketing, INN, Woman, Allergy, ATC, Absorption, Hormone, Pain, International, Diet, Pancreas, Insulin, Disease, Diabetes, Metformin, Blood, Nausea, Somatic symptom disorder, Language, DPP-4, Type, Glucose, European Medicines Agency, Type 2 diabetes, Food, Metabolic acidosis, Kidney, Tablet, Select, Alcoholism, Anatomy, Vildagliptin, IIA, Exercise, Vomiting, Medical device

Human medicines European public assessment report (EPAR): Zomarist, vildagliptin,metformin, Date of authorisation: 30/11/2008, Revision: 24, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Zomarist, vildagliptin,metformin, Date of authorisation: 30/11/2008, Revision: 24, Status: Authorised

Global Dipeptidyl Peptidase 4 (DPP-4) Inhibitors Markets 2020-2021 & 2026: Focus on Sitagliptin, Vildagliptin, Saxagliptin, Linagliptin, Gemigliptin, Anagliptin, Teneligliptin, and Others - ResearchAndMarkets.com

Retrieved on: 
Monday, September 20, 2021
Health, Pharmaceutical, DPP-4, Linagliptin, Vildagliptin, Bristol-Myers Squibb Co. v. Superior Court, IDF, Merck & Co., GlaxoSmithKline, Diabetes, Novartis, Growth, Prevalence, E-64, International Diabetes Federation, Anagliptin, Pharmaceutical industry, Fine chemical

The dipeptidyl peptidase 4 (DPP-4) inhibitors aids in the release of insulin secretion in the patients' body and regulates the sugar levels in the body.

Key Points: 
  • The dipeptidyl peptidase 4 (DPP-4) inhibitors aids in the release of insulin secretion in the patients' body and regulates the sugar levels in the body.
  • However, numerous side effects associated with the intake of dipeptidyl peptidase 4 (DPP-4) inhibitors in form of drugs challenge the growth of the market.
  • The global dipeptidyl peptidase 4 (DPP-4) inhibitors market is segmented on the basis of drug type.
  • Geographically, the global dipeptidyl peptidase 4 (DPP-4) inhibitors market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World.

Dipeptidyl Peptidase 4 Inhibitors Pipeline Research Report 2021 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, July 7, 2021
Health, Diabetes, Proteases, Dipeptidyl peptidase-4 inhibitors, Dipeptidyl peptidase, Nitriles, Chemistry, Organic compounds, Chemical compounds, Tertiary alcohols, Piperidines, Dipeptidyl-peptidase IV family, Vildagliptin

The "Dipeptidyl Peptidase 4 Inhibitors - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Dipeptidyl Peptidase 4 Inhibitors - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • This "Dipeptidyl peptidase 4 inhibitors - Pipeline Insight, 2021" report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in Dipeptidyl peptidase 4 inhibitors pipeline landscape.
  • The companies and academics are working to assess challenges and seek opportunities that could influence Dipeptidyl peptidase 4 inhibitors R&D.
  • Dipeptidyl peptidase 4 inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

Global and Chinese Market Vildagliptin Market Insights, 2014-2019 & 2019-2024 by Manufacturers, Product Type, Application, and Technology - ResearchAndMarkets.com

Retrieved on: 
Wednesday, September 11, 2019
Health, Pharmaceutical, Organic compounds, Chemical compounds, Chemistry, Dipeptidyl peptidase-4 inhibitors, Nitriles, Pyrrolidines, Vildagliptin, Economy of China

The "Vildagliptin Market Insights 2019, Analysis and Forecast Global and Chinese Market to 2024, by Manufacturers, Product Type, Application, Regions and Technology" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Vildagliptin Market Insights 2019, Analysis and Forecast Global and Chinese Market to 2024, by Manufacturers, Product Type, Application, Regions and Technology" report has been added to ResearchAndMarkets.com's offering.
  • Vildagliptin Market Insights 2019, Global and Chinese Scenario is a professional and in-depth study on the current state of the global Vildagliptin industry with a focus on the Chinese market.
  • Overall, the report provides an in-depth insight of 2014-2024 Global and Chinese Vildagliptin market covering all important parameters.
  • Through the statistical analysis, the report depicts the Global and Chinese total market of Vildagliptin industry including capacity, production, production value, cost/profit, supply/demand and Chinese import/export.

Dipeptide Peptidase 4 (DPP-4) Inhibitors: Global Market 2019-2024 - The Tradjenta Market will Surpass Merck's Januvia During the Forecast Period - ResearchAndMarkets.com

Retrieved on: 
Wednesday, April 3, 2019
Health, Pharmaceutical, Chemical compounds, Dipeptidyl peptidase-4 inhibitors, Organic compounds, Chemistry, Dipeptidyl peptidase-4, Sitagliptin, Linagliptin, Forecast period, Compound annual growth rate, Vildagliptin

The "Dipeptide Peptidase 4 (DPP-4) Inhibitors Market - Growth, Trends, and Forecast (2019 - 2024)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Dipeptide Peptidase 4 (DPP-4) Inhibitors Market - Growth, Trends, and Forecast (2019 - 2024)" report has been added to ResearchAndMarkets.com's offering.
  • Increase in clinical trials on the DPP-4 drugs will also boost the market growth in the forecast period.
  • The global Tradjenta market is expected to register a CAGR of 5.7 %, during the forecast period, 2019-2024, and is expected to surpass the Januvia market, which held the maximum market share in 2018.
  • The Asia-Pacific holds 32% of the market share in the global DPP-4 market, followed by North America, which holds the highest market share.

Global DPP-IV Inhibitors Industry

Retrieved on: 
Wednesday, October 17, 2018
Chemistry, Dipeptidyl peptidase-4 inhibitors, Organic chemistry, Sitagliptin, Saxagliptin, Linagliptin, Vildagliptin, Alogliptin, Daiichi Sankyo, Discovery and development of dipeptidyl peptidase-4 inhibitors, Omarigliptin

Major DPP-4 Inhibitors on the Market: List of Brand, Preparation, Manufacturer, Daily Treatment Cost, FDA Approval Date and Patent Expiration Date

Key Points: 
  • Major DPP-4 Inhibitors on the Market: List of Brand, Preparation, Manufacturer, Daily Treatment Cost, FDA Approval Date and Patent Expiration Date
    Table 1: Global DPP-4 Inhibitor Market by Top Five Drug Class (2018): Market Share Breakdown of Revenues (In %) for Januvia/Janumet, Galvus, Onglyza, Tradjenta, and Nesina (includes corresponding Graph/Chart)
    TECOS Results Prove No Link of Januvia with CVD Events; However, FDA Adds Heart Failure Warning to Label
    Table 2: Prices of Select Dpp4 and Sglt-2 Inhibitors: Single and Combination Drugs
    Table 10: Healthcare Spending (in US$ Billion) by People with Diabetes (20-79 Years) for the Years 2011, 2013, 2015 and 2017 (includes corresponding Graph/Chart)
    Table 14: World 10-Year Perspective for Januvia (Sitagliptin) Franchise Sales Breakdown for Years 2015, 2018 and 2024 for the US and RoW (includes corresponding Graph/Chart)
    Table 17: Global 10-Year Perspective for Onglyza (Saxagliptin) Sales Breakdown for Years 2015, 2018 and 2
    Table 19: Global 10-Year Perspective for Tradjenta (Linagliptin) Sales Breakdown for Years 2015, 2018 and 2
    Table 21: Global 10-Year Perspective for Nesina (Alogliptin): Annual Sales Breakdown for Years 2015, 2018 and 2024 for the US and RoW (includes corresponding Graph/Chart)
    TENELIA (Mitsubishi Tanabe & Daiichi Sankyo Co., Ltd.)
    Mitsubishi Tanabe Pharma Corporation and Daiichi Sankyo Co., Ltd.
  • Announces the Launch of CANALIA Combination Tablets
    Table 22: World Recent Past, Current and Future Analysis for DPP-IV Inhibitors by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2024 (includes corresponding Graph/Chart)
    Table 23: World 10-Year Perspective for DPP-IV Inhibitors by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets for Years 2015, 2018 and 2024 (includes corresponding Graph/Chart)
    Table 24: World Recent Past, Current and Future Analysis for DPP-IV Inhibitors by Drug Compound - Sitagliptin, Saxagliptin, Vildagliptin, and Others Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2024 (includes corresponding Graph/Chart)
    Table 25: World 10-Year Perspective for DPP-IV Inhibitors by Drug Compound - Percentage Breakdown of Dollar Sales for Sitagliptin, Saxagliptin, Vildagliptin, and Others Markets for Years 2015, 2018 and 2024 (includes corresponding Graph/Chart)
    Table 27: World 10-Year Perspective for Sitagliptin by Geographic Region - Percentage Breakdown of Dollar Sales for US and Rest of World Markets for Years 2015, 2018 and 2
    Table 29: World 10-Year Perspective for Saxagliptin by Geographic Region - Percentage Breakdown of Dollar Sales for US and Rest of World Markets for Years 2015, 2018 and 2
    Table 31: World 10-Year Perspective for Linagliptin by Geographic Region - Percentage Breakdown of Dollar Sales for US and Rest of World Markets for Years 2015, 2018 and 2
    Table 33: World 10-Year Perspective for Alogliptin by Geographic Region - Percentage Breakdown of Dollar Sales for US and Rest of World Markets for Years 2015, 2018 and 2

New Review of Clinical Safety and Tolerability of Vildagliptin - Insights from Randomised Trials, Observational Studies and Post-marketing Surveillance - touchENDOCRINOLOGY

Retrieved on: 
Tuesday, April 24, 2018
Chemistry, Dipeptidyl peptidase-4 inhibitors, Organic chemistry, Alcohols, Nitriles, Pyrrolidines, Vildagliptin, Novartis, Tolerability, Gemigliptin

Over the last decade, a vast panorama of evidence on the benefit-risk profile of vildagliptin has been generated in patients with type 2 diabetes mellitus (T2DM).

Key Points: 
  • Over the last decade, a vast panorama of evidence on the benefit-risk profile of vildagliptin has been generated in patients with type 2 diabetes mellitus (T2DM).
  • In this article, we review the cumulative evidence on the safety of vildagliptin from the clinical development programme, as well as reports of rare adverse drug reactions detected during the post-marketing surveillance of the drug.
  • Across clinical studies, the overall safety and tolerability profile of vildagliptin was similar to placebo, and it was supported by real-world data in a broad population of patients with T2DM, making DPP-4 inhibitors, like vildagliptin, a safe option for managing patients with T2DM.
  • Plamen Kozlovski, Pivi M Paldnius, Vikas Modgill and Carmen Serban are employees and shareholders of Novartis Pharma AG.